New Products

Mar 22, 2017

FDNA Face2Gene Research Application

FDNA has launched Face2Gene Research, an application that uses facial analysis, deep learning, and artificial intelligence to analyze patient cohorts to make clinical genomic discoveries. The application allows clinicians to de-identify medical data from their patients to discover syndrome phenotypes; compare phenotypes, genes, and gestalts among multiple cohorts; compare syndrome or gene cohorts to a normal population; expand data collection; and offer collaboration opportunities.

Mar 22, 2017

EntroGen Colorectal Cancer Panel, Thyroid Cancer Mutation and Fusion Gene Detection Kits

EntroGen has launched its Colorectal Cancer panel, Thyroid Cancer Mutation Analysis kit, and Thyroid Cancer Fusion Gene Detection kit. The panel is a PCR-based, highly multiplexed assay that allows consumers to screen or 50 somatic mutations in oncogenes associated with colorectal cancer tumors (KRAS, NRAS, BRAF, PIK3CA, and AKT). It is compatible with formalin fixed paraffin embedded and fresh frozen tissue. The Thyroid Cancer Mutation Analysis kit and Thyroid Cancer Fusion Gene Detection kit are multiplexed PCR-based assays that prevent unnecessary surgeries due to indeterminate cytology specimens, the company said. The mutation analysis kit detects point mutations in BRAF, KRAS, NRAS, and HRAS is isolated DNA. The fusion gene detection kit detects the chromosomal translocation RET/PTC1, and PAX8/PPARy in RNA. These kits are compatible with FFPE, fine needle aspiration, and fresh frozen samples. All three products have received the CE-IVD mark.

Mar 22, 2017

Invitae Spinal Muscular Atrophy Test

Invitae launched a new genetic test for diagnosing spinal muscular atrophy (SMA), a neuromuscular disease that impacts infants' ability to walk, crawl, and eventually breath and swallow, and can be lethal. The company claims that its genetic test is an improvement over currently available methods. Affecting one in every 10,000 infants, SMA is an autosomal recessive disorder that is usually caused by the loss of SMN1 gene, while variations in the number of copies of SMN2 contributes to disease severity. Accurately gauging both sequence changes in SMN1 and copy number changes in SMN2 has been challenging in the past, but the company said in a statement it is hoping to address this with its next-generation sequencing test and customized bioinformatics solution. Invitae is offering analysis of SMN1 and SMN2 as a standalone test, and adding the genes to its neuromuscular and neuropathy panels.

Mar 21, 2017

Agilent SureSelect Clinical Research Exome V2

Agilent Technologies has introduced a new target enrichment technology for next-generation sequencing. The SureSelect Clinical Research Exome V2 adds coverage for 1,099 additional disease-relevant targets, 75,000 splice sites of noncoding exons, more than 12,000 deep intronic variants, and more than 800 variants in promoter regions. The targets were curated in collaboration with Emory University and the Children's Hospital of Philadelphia.

Mar 17, 2017

Roche MagNA Pure 24

Roche has launched the MagNA Pure 24 System for nucleic acid extraction and purification. The fully automated, magnetic bead-based clinical sample extractor features walk-away automation and provides on-board primary sample handling for low to medium throughputs. The system, which is IVD/CE-IVD labeled, also provides extraction from a wide range of human sample types with a single universal reagent kit.

Mar 16, 2017

Phosphorus Genetic Tests for Inherited Cardiology Diseases

Phosphorus has launched genetic tests of inherited conditions associated with early onset cardiovascular disease. The tests include a comprehensive panel of genes based on the latest advances in cardiovascular disease research and are powered by next-generation sequencing technology, including detection of copy number variants, the company said. The panels include genes associated with cardiomyopathies, arrhythmias, and familial hypercholesterolemia.

Mar 15, 2017

Thermo Fisher Scientific QuantStudio 5 Real-Time PCR System

Thermo Fisher Scientific has launched the Applied Biosystems QuantStudio 5 Real-Time PCR system for human identification. The system is designed to deliver efficient performance with a smaller footprint and lower annual maintenance costs, the company said. It has been optimized with the new HID Real-Time PCR Analysis Software v1.3, which allows researcher to perform data analysis with a virtual standard curve feature to minimize variation and reduce costs associated with using standards on every plate. The software also includes quantification and short tandem repeat setup features.

Mar 15, 2017

Omic Analytics Proteolabels

Omic Analytics has launched Proteolabels, a new proteomics-focused plugin for Progenesis QI, the mass spectrometry analysis software from Waters subsidiary Nonlinear Dynamics. Proteolabels supports research involving stable isotope labels, such as stable isotope labeling with amino acids in cell culture (SILAC) and dimethyl labeling in duplex or triplex. The plugin offers features such as co-detection, auto-detection, peptide scoring, intelligent protein inference, and quality control metrics. It will be available exclusively through Waters.

Mar 15, 2017

Eurofins Next Generation DNA Synthesis Service

Eurofins Genomics has launched its DNA synthesis service, which is designed to supply both small and large quantities of high-quality oligonucleotides. The services uses the company's next-generation synthesis platform. For order in the US and Canada, oligos meeting the specified scale, length, and purification criteria and placed as late as 5:00 p.m. are eligible for same-day synthesis and overnight shipping for no additional surcharge, the company said.

Mar 15, 2017

Agena UltraSeek Lung and Colon Panels

Agena Bioscience has launched the UltraSeek Lung and Colon panels for the detection of somatic mutations from lung and colon cancers. The panels enable mutation profiling of circulating tumor DNA and circulating tumor cells from plasma and solid tumor tissue. They also target mutations of known significance in BRAF, EGFR, ERBB2, KRAS, NRAS, and PIK3CA genes. The panels can work with DNA extracted from a single 10 mL blood draw and can detect mutations as low as 0.1 percent minor allele frequency, the company said.

Mar 15, 2017

Myriad Genetics EndoPredict Test

Myriad Genetics has launched the EndoPredict test, a second-generation test for assessing the 10-year risk of disease recurrence in patients with ER+ HER2- early-stage breast cancer. The test includes proliferation-related genes and hormone receptor-related genes to provide clinicians with an accurate assessment of early and late risk recurrence, the company said. It uses this information to definitively classify patients as low or high risk, which helps clinicians make therapy decisions going forward.

Mar 14, 2017

Asuragen AmplideX PCR/CE TOMM40 Kit

Asuragen has launched a kit in its AmplideX line to detect poly-T polymorphisms in the TOMM40 gene using PCR and capillary electrophoresis. The AmplideX PCR/CE TOMM40 Kit expands the firm's portfolio into the neurodegeneration, dementia progression, and Alzheimer’s disease research space. It builds on the Asuragen's success with its FMR1 and C9orf72 kits, which also reveal definitive genotypes from repetitive DNA and overcome challenges associated with high homology sequences.

Mar 14, 2017

PreventionGenetics PGxome Custom Panels

PreventionGenetics has launched new customizable whole-exome next-generation sequencing panels for clinical genetic testing. The PGxome Custom Panels can be ordered to contain any subset of more than 4,000 clinically relevant or disease-causing genes, including paralogous genes, enabling gap coverage in whole-exome NGS-based testing. 

Mar 10, 2017

MagBio CfKapture 21 System

MagBio Genomics has launched its cfKapture 21 kit, which isolates cell-free DNA in plasma samples. The kit include a proprietary reagent that prevents post-separation degradation of plasma and ccfDNA fragments for up to 21 days at room temperature. It is compatible with any whole blood collection tube and is for research use only.

Mar 09, 2017

Sygnis TrueAdvance Amplification Service

Sygnis has launched a new service to address quality needs in next-generation sequencing. Called TrueAdvance, the service will use Sygnis' TruePrime amplification technology as well as a sample validation service based on its CovCheck technology to confirm that amplified DNA is of high quality and suitable for NGS. The service aims to support and enable single cell and liquid biopsy applications.

Mar 09, 2017

Canon Novallele Cystic Fibrosis Genotyping Assays

Canon Biomedical has launched a series of cystic fibrosis genotyping assays as part of its Novallele line. Novallele assays detect genetic variations using PCR followed by high-resolution melting analysis and can be used on any thermocycler capable of HRM. The 21 new tests are for research use to detect SNPs and deletions within the CFTR gene.

Mar 08, 2017

Med Fusion LungSEQ and 50SEQ Plus FISH Laboratory Service Expansion

GenomOncology and med fusion announced the expansion of med fusion's LungSEQ and 50SEQ Plus FISH laboratory services to include PD-L1 expression testing. The original services provided a variety of testing services for patients with non-small cell lung cancer. The panels expansion to test results or the status of PD-L1 will determine if patients may be eligible for new-FDA immunotherapies, the companies said.

Mar 07, 2017

GenPath Women's Health ClariTest

GenPath Women's Health, a business unit of BioReference Laboratories, is offering ClariTest, a noninvasive prenatal test that will be initially performed at Illumina. The test leverages massively parallel sequencing technology to screen for trisomies 13, 18, and 21, and sex chromosome abnormalities. It also offers the option to screen for five microdeletions, including 22q11.2, or DiGeorge syndrome. The company said that it will ultimately develop and validate its own laboratory-developed NIPT using Illumina technology.

Mar 07, 2017

Agilent 6545XT AdvanceBio LC/Q-TOF MS System and Peptide Plus Column

Agilent Technologies has released a new mass spectrometry instrument designed for biomolecule characterization in drug development research. The research-grade 6545XT AdvanceBio pairs high-performance liquid chromatography with quadrupole time-of-flight mass spec and the firm's data-analysis tools. Agilent has also optimized the instrument for profiling intact proteins, mapping peptides, and identifying post-translational modifications. The firm also launched the new Peptide Plus LC column for peptide separations, incorporating superficially porous particle technology.

Mar 07, 2017

IncellDx PD-L1 Assay

IncellDx has released a new single-cell PD-L1 assay for research use only. The new "OncoTect iO Quantitative" test kit includes labeled antibodies to PD-L1 and CD45, CD8, and CD3 cell subsets as well as a DNA dye for cell cycle and quantitative detection of PD-L1 expression in non-small cell lung cancer tissue. According to the company, kits can be used on numerous samples types including FNA, core biopsies, and blood. The assay is also applicable to tumor types other than NSCLC including lung, bladder, and head and neck cancers.

Mar 07, 2017

CureMatch Decision Support Software

CureMatch has launched their decision support software platform to select combinations of cancer therapies based on tumor molecular profiling. The software considers data from clinical trials, publications, and drug interaction databases, along with the patient's genetic profile, to comb through more than 4.5 million possible combination therapy options. 

Mar 07, 2017

Vela Genomics NGS Clinical Interpretation and Reporting

Vela Genomics, a subsidiary of Vela Diagnostics, has launched TheraKey, a cloud-based, HIPAA-compliant, next-generation sequencing clinical interpretation and reporting solution. The TheraKey database includes somatic cancer mutations in more than 800 genes, sourced from approximately 220,000 clinical trials for about 2,000 cancer drugs. It also offers natural language processing to facilitate reporting of actionable treatments, including off-label, investigational, and combination therapies for specific diseases or gene variants. The firm will also offer TheraKey as part of its Sentosa NGS workflow for Oncology.

Mar 06, 2017

Thermo Fisher Scientific iCAP TQ ICP-MS

Thermo Fisher Scientific has introduced the Thermo Scientific iCAP Triple-Quadrupole Inductively Coupled Plasma Mass Spectrometry (iCAP TQ ICP-MS) system. It is designed for a range of applications, including clinical research and pharmaceutical quality assurance and control. The system is an extension of Thermo's existing iCAP line and combines increased power with simplified operations.

Mar 03, 2017

Sage Science SageHLS Platform

Sage Science has launched SageHLS, a platform designed to extract and purify extremely large DNA fragments directly from bacterial and tissue cultures, blood samples, or other cell sources. SageHLS can purify DNA into fragments ranging from 50 kilobases to 2 megabases, providing the long fragments needed for resolving haplotypes, structural variants, and other large or linkled genomic elements. For most samples, SageHLS can recover at least a microgram of DNA, a sufficient volume for common genome applications. Users can currently perform traditional library prep after purification on the platform, but later versions will directly incorporate this step for a more streamlined workflow, Sage Science said.

Mar 03, 2017

DNAStar Lasergene 14.1

DNAStar has launched Lasergene 14.1. The new release includes improvements to each of the major software platforms — Molecular Biology, Genomics, and Structural Biology. The company also added automated plasmid annotation to the Lasergene Molecular Biology Suite, and the Lasergene Genomics Suite now includes advanced mRNA isoform analysis via Sashimi plots. The Structural Biology Suite now includes features annotation within Protean 3D for more robust protein analysis. The release also includes enhanced integration and visualization of sets between applications, updated databases, and integration with PowerPoint for advanced editing in presentations, DNAStar said.

Pages

In Nature this week: paternal age associated with de novo mutations in children, and more.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.